PMID- 15000310
OWN - NLM
STAT- MEDLINE
DCOM- 20040726
LR  - 20061115
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 13
IP  - 6
DP  - 2003 Dec
TI  - [Neuroendocrine cancer of the prostate. A series of 6 cases].
PG  - 1340-4
AB  - INTRODUCTION: Neuroendocrine cancer of the prostate (NECP) is a rare entity. 
      Screening for this tumour, although not systematic, may have therapeutic 
      implications. The authors retrospectively evaluated 6 cases of NECP observed in 
      the department between September 1998 and May 2002. MATERIAL AND METHODS: The 
      diagnosis was based on immunohistochemical analysis of biopsy fragments with the 
      presence of marked neuroendocrine differentiation (minimum 50%). Positive 
      staining for anti-Neuron-Specific Enolase (NSE) and anti-Chromogranin A 
      antibodies was observed in 5 and 6 cases, respectively, while anti-PSA antibody 
      labelling was always negative. RESULTS: NECP represented 2.1% of all prostate 
      cancers diagnosed in the department over the same period. Digital rectal 
      examination was abnormal in every case with a median PSA of 9.75 ng/ml (range: 
      0.25-19.6). Three patients presented metastatic disease at the time of the 
      diagnosis. Four of the 6 patients were urgently admitted to hospital because of 
      acute clinical features. Paroxysmal abdominal pain occurred during the course of 
      the disease in every case with a median of 52 days (range: 22-198) and was 
      initially present in 2 cases. Chemotherapy was performed in 3 cases and 
      palliative therapy was administered in the other cases. A survival difference was 
      observed for patients treated by chemotherapy (13 months versus 4.7). The median 
      survival was 9 months and 14 days. Death occurred in a context of rapid 
      alteration of the general state and renal function. CONCLUSION: NECP has a poor 
      prognosis. Clinical and complementary features guide the diagnosis, which can be 
      confirmed by immunohistochemical analysis, allowing early management based on 
      chemotherapy.
FAU - Breton, Xavier
AU  - Breton X
AD  - Service d'Urologie, CHU La Miletrie, Poitiers, France. xbreton@wanadoo.fr
FAU - Plazanet, Caroline
AU  - Plazanet C
FAU - Murat, Francois Joseph
AU  - Murat FJ
FAU - Milinkevitch, Serge
AU  - Milinkevitch S
FAU - Irani, Jacques
AU  - Irani J
FAU - Levillain, Pierre
AU  - Levillain P
FAU - Dore, Bertrand
AU  - Dore B
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Cancer neuroendocrine de la prostate. A propos de 6 cas.
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroendocrine Tumors/*diagnosis/therapy
MH  - Prostatic Neoplasms/*diagnosis/therapy
MH  - Retrospective Studies
EDAT- 2004/03/06 05:00
MHDA- 2004/07/28 05:00
CRDT- 2004/03/06 05:00
PHST- 2004/03/06 05:00 [pubmed]
PHST- 2004/07/28 05:00 [medline]
PHST- 2004/03/06 05:00 [entrez]
PST - ppublish
SO  - Prog Urol. 2003 Dec;13(6):1340-4.